Mirum's Livmarli cuts itching in ultra-rare liver disease trial, showing significant benefit

Mirum Pharmaceuticals reported that its ileal bile acid transporter inhibitor Livmarli achieved a statistically significant reduction in cholestatic pruritus compared with placebo in a late‑stage study of patients with ultra‑rare cholestatic liver diseases, including biliary atresia.

The trial enrolled participants with severe itching that is a hallmark of cholestasis. Patients receiving Livmarli experienced marked relief, suggesting the drug’s ability to modulate bile acid pathways and improve quality of life for this difficult‑to‑treat population.

In the same briefing, First Tracks announced progress on its celiac disease program, though details were limited. The dual announcements highlight ongoing innovation in niche therapeutic areas.